Exercise-Induced Hepatocyte Growth Factor Production in Patients after Acute Myocardial Infarction - Its Relationship to Exercise Capacity and Brain Natriuretic Peptide Levels

Circulation Journal

Volumn 68, Issue 4, 2004, Pages 304-307

  Yasuda, Satoshi ^a   Goto, Yoichi ^a   Takaki, Hiroshi ^a   Asaumi, Yasuhide ^a   Baba, Takeshi ^a   Miyazaki, Shunichi ^a   Nonogi, Hirohi ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Exercise; Growth substances; Myocardial infarction; Rehabilitation

Indexed keywords

BIOCHEMICAL MARKER; BRAIN NATRIURETIC PEPTIDE; SCATTER FACTOR;

ACUTE DISEASE; ADULT; AGED; ANALYTICAL PARAMETERS; AORTA; ARTICLE; CALCULATION; CARDIOVASCULAR FUNCTION; CATHETERIZATION; CLINICAL ARTICLE; EXERCISE; EXERCISE TEST; HEART INFARCTION; HEART OUTPUT; HEART VENTRICLE REMODELING; HUMAN; MALE; MATHEMATICAL COMPUTING; MEASUREMENT; OXYGEN CONSUMPTION; PROTEIN SYNTHESIS; PULMONARY ARTERY; STATISTICAL SIGNIFICANCE; SYMPTOM;

AGED; CONVALESCENCE; EXERCISE; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; HEART RATE; HEPATOCYTE GROWTH FACTOR; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NATRIURETIC PEPTIDE, BRAIN; OXYGEN CONSUMPTION; SUPINE POSITION; VENTRICULAR REMODELING;

EID: 1842783400     PISSN: 13469843     EISSN: None     Source Type: Journal    
DOI: 10.1253/circj.68.304     Document Type: Article

References (30)

1. Nakamura T, Nishizawa T, Hagiya M, Seki T, Shimonishi M, Sugimura A, et al. Molecular cloning and expression of hepatocyte growth factor. Nature (Lond.) 1989; 342: 440-443.
2. Boros P, Miller CM. Hepatocyte growth factor: A multifunctional cytokine. Lancet 1995; 345: 293-295.
3. Nakamura Y, Morishita R, Nakamura S, Aoki M, Moriguchi A, Matsumoto K, et al. A vascular modulator, hepatocyte growth factor, is associated with systolic pressure. Hypertension 1996; 28: 409-413.
4. Nakano N, Moriguchi A, Morishia R, Kida I, Tomita N, Matsumoto K, et al. Role of angiotensin II in the regulation of a novel vascular modulator, hepatocyte growth factor (HGF), in experimental hypertensive rats. Hypertension 1997; 30: 1448-1454.
5. Nakagami H, Morishita R, Yamamoto K, Taniyama Y, Aoki M, Kim S, et al. Anti-apoptotic action of hepatocyte growth factor through mitogen-activated protein kinase on human aortic endothelial cells. J Hypertens 2000; 18: 1411-1420.
6. Nakamura T, Mizuno S, Matsumoto K, Sawa Y, Matsuda H, Nakamura T. Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF. J Clin Invest 2000; 106: 1511-1519.
7. Taniyama Y, Morishita R, Nakagami H, Moriguchi A, Sakonjo H, Kim S, et al. Potential contribution of a novel antifibrotic factor, hepatocyte growth factor, to prevention of myocardial fibrosis by angiotensin II blockade in cardiomyopathic hamsters. Circulation 2000; 102: 246-252.
8. Ueda H, Nakamura T, Matsumoto K, Sawa Y, Matsuda H, Nakamura T. A potential cardioprotective role of hepatocyte growth factor in myocardial infarction in rats. Cardiovasc Res 2001; 51: 41-50.
9. Morishita R. Recent progress in gene therapy for cardiovascular disease. Circ J 2002; 66: 1077-1086.
10. Ades PA. Cardiac rehabilitation and secondary prevention of coronary heart disease. N Engl J Med 2001; 345: 892-902.
11. Dubach P, Myers J, Dziekan G, Goebbels U, Reinhart W, Vogt P, et al. Effect of exercise training on myocardial remodeling in patients with reduced left ventricular function after myocardial infarction: Application of magnetic resonance imaging. Circulation 1997; 95: 2060-2067.
12. Giannuzzi P, Temporelli PL, Corra U, Gattone M, Giordano A, Tavazzi L. Attenuation of unfavorable remodeling by exercise training in postinfarction patients with left ventricular dysfunction: Results of the Exercise in Left Ventricular Dysfunction (ELVD) trial. Circulation 1997; 96: 1790-1797.
13. Nagaya N, Nishikimi T, Goto Y, Miyao Y, Kobayashi Y, Morii I, et al. Plasma brain natriuretic peptide is a biochemical marker for the prediction of progressive ventricular remodeling after acute myocardial infarction. Am Heart J 1998; 135: 21-28.
14. Richardson RS, Wagner H, Mudaliar SR, Saucedo E, Henry R, Wagner PD. Exercise adaptation attenuates VEGF gene expression in human skeletal muscle. Am J Physiol 2000; 279: H772-H778.
15. Sessa WC, Pritchard K, Seyedi N, Wang J, Hintze TH. Chronic exercise in dogs increases coronary vascular nitric oxide production and endothelial cell nitric oxide synthase gene expression. Circ Res 1994; 74: 349-353.
16. Gielen S, Schuler G, Hambrecht R. Exercise training in coronary artery disease and coronary vasomotion. Circulation 2001; 103: E1-E6.
17. Yasuda S, Goto Y, Sumida H, Noguchi T, Baba T, Miyazaki S, et al. Angiotensin-converting enzyme inhibition restores hepatocyte growth factor production in patients with congestive heart failure. Hypertension 1999; 33: 1374-1378.
18. Tsubouchi H, Niitani Y, Hiroko S, Nakayama H, Gohda E, Arakaki N, et al. Levels of the human hepatocyte growth factor in serum of patients with various diseases determined by an enzyme-linked immunosorbent assay. Hepatology 1991; 13: 1-5.
19. Arakaki N, Kawakami S, Nakamura O, Ohnishi T, Miyazaki H, Ishi T, et al. Evidence of the presence of an inactive precursor of human hepatocyte growth factor in plasma and sera of patients with liver diseases. Hepatology 1995; 22: 1728-1784.
20. Pina IL, Apstein CS, Balady GJ, Belardinelli R, Chaitman BR, Duscha BD, et al. American Heart Association Committee on exercise, rehabilitation, and prevention. Exercise and heart failure: A statement from the American Heart Association Committee on exercise, rehabilitation, and prevention. Circulation 2003; 107: 1210-1225.
21. White HD, Norris RM, Brown MA, Brandt PW, Whitlock RM, Wild CJ. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 1987; 76: 44-51.
22. Niebauer J, Cooke JP. Cardiovascular effects of exercise: Role of endothelial shear stress. J Am Coll Cardiol 1996; 28: 1652-1660.
23. Wajih N, Walter J, Sane DC. Vascular origin of a soluble truncated form of the hepatocyte growth factor receptor (c-met). Circ Res 2002; 90: 46-52.
24. Ono K, Matsumori A, Shioi T, Furukawa Y, Sasayama S. Enhanced expression of hepatocyte growth factor/c-Met by myocardial ischemia and reperfusion in a rat model. Circulation 1997; 95: 2552-2558.
25. Belle EV, Witzenbichler B, Chen D, Silver M, Chang L, Schwall R, et al. Potential angiogenetic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor. The case for paracrine amplification of angiogenesis. Circulation 1998; 97: 381-390.
26. Hayashi K, Nakamura S, Morishita R, Moriguchi A, Aoki M, Matsumoto K, et al. In vivo transfer of human hepatocyte growth factor gene accelerates re-endothelialization and inhibits neointimal formation after balloon injury in rat model. Gene Therapy 2000; 7: 1664-1671.
27. Shimada Y, Yoshiyama M, Jissho S, Kamimori K, Nakamura Y, Iida H, et al. Hepatocyte growth factor production may be related to the inflammatory response in patients with acute myocardial infarction. Circ J 2002; 66: 253-256.
28. Li Y, Takemura G, Kosai K, Yuge K, Nagano S, Esaki M, et al. Postinfarction treatment with an adenoviral vector expressing hepatocyte growth factor relieves chronic left ventricular remodeling and dysfunction in mice. Circulation 2003; 107: 2499-2506.
29. Heeschen C, Dimmeler S, Hamm CW, Boersma E, Zeiher AM, Simoons ML. CAPTURE (c7E3 Anti-Platelet Therapy in Unstable REfractory angina) Investigators. Prognostic significance of angiogenic growth factor serum levels in patients with acute coronary syndromes. Circulation 2003; 107: 524-530.
30. Lenihan DJ, Osman A, Sriram V, Aitsebaomo J, Patterson C. Evidence for association of coronary sinus levels of hepatocyte growth factor and collateralization in human coronary disease. Am J Physiol 2003; 284: H1507-H1512.